Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits. Here is our analysis of the results.
|Other operating income||352||2,294||551.0%||2,850||9,668||239.2%|
|Operating profit (EBDITA)||22,456||24,532||9.2%||58,864||85,418||45.1%|
|EBDITA margin (%)||31.5%||31.0%||28.4%||35.0%|
|Profit before tax||20,401||21,020||3.0%||51,689||76,591||48.2%|
|Profit after tax/(loss)||15,449||14,718||-4.7%||31,296||57,407||83.4%|
|Net profit margin (%)||21.8%||19.2%||15.3%||24.5%|
|No. of shares (m)||2,407.0|
|Adj Diluted earnings per share (Rs)||29.9|
|Price to earnings ratio (x)*||22.6|
|DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537.
An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes.
There are no outstanding litigations against the Company, it subsidiaries and its Directors.
GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT:
For the terms and conditions for research reports click here.
DETAILS OF ASSOCIATES:
Details of Associates are available here.
DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us.